Journavx for Pain Management: Toward Affordabil...

By Rene Pretorius

April 25, 2025

In this review I summarize the ICER 2025 evaluation report of suzetrigine (Journavx®), a new FDA-approved non-opioid oral analgesic. It targets the N...
Defunding Scientific Research: Implications and Misconceptions in GawandeR...
Optimizing Value-Based Drug Pricing in Japan with MARIE Framework
Targeting Shared Risk Pathways to Prevent Stroke, Dementia, and Depression
Navigating Drug Price Regulation: Evaluating the Executive Order’s Pote...
NICE Grants Conditional Robotic Surgery Approval to Enhance Patient Care and ...
Cost-Effective HIV PrEP: CAB-LA Transforms Prevention
Global Health Limitations: A Critical Assessment of Structural Constraints an...
Enhancing UK Clinical Trials Inclusivity: Opportunities and Innovations in Me...
Cost-Effective Interventions for HIV, Malaria, Syphilis, and TB in 128 Countries
Advancing Early Childhood Health: PureHealth’s Partnership with Abu Dha...
Balancing Pandemic Preparedness Priorities and Military Spending
Reassuring the Private Sector on National Health Insurance South Africa: A Pa...